TickerFacts.

Biogen Inc. (BIIB): Long-Term Debt

Annual figures by period end, from SEC filings.

$6.29B
As of 2025-12-31
$6.29B
As of 2026-03-31
0.0%
3-year compound annual growth
-3.3%
5-year compound annual growth
-0.4%
10-year compound annual growth
$7.43B2010-12-31: $1.04B2011-12-31: $1.02B2012-12-31: $687.40M2013-12-31: $592.43M2014-12-31: $580.30M2015-12-31: $6.52B2016-12-31: $6.51B2017-12-31: $5.93B2018-12-31: $5.94B2019-12-31: $4.46B2020-12-31: $7.43B2021-12-31: $6.27B2022-12-31: $6.28B2023-12-31: $6.94B2024-12-31: $6.30B2025-12-31: $6.29B$6.29B
2010-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$6.29B-0.1%2026-02-06, Balance as of period end
2024-12-31$6.30B-9.3%2025-02-12, Balance as of period end
2023-12-31$6.94B+10.5%2024-02-14, Balance as of period end
2022-12-31$6.28B+0.1%2023-02-15, Balance as of period end
2021-12-31$6.27B-15.5%2023-02-15, Balance as of period end
2020-12-31$7.43B+66.5%2022-02-03, Balance as of period end
2019-12-31$4.46B-24.9%2021-02-03, Balance as of period end
2018-12-31$5.94B0.0%2020-02-06, Balance as of period end
2017-12-31$5.93B-8.9%2019-02-06, Balance as of period end
2016-12-31$6.51B-0.1%2018-02-01, Balance as of period end
2015-12-31$6.52Bn/m2017-02-02, Balance as of period end
2014-12-31$580.30M-2.0%2016-02-03, Balance as of period end
2013-12-31$592.43M-13.8%2015-02-04, Balance as of period end
2012-12-31$687.40M-32.9%2014-02-06, Balance as of period end
2011-12-31$1.02B-1.1%2012-02-03, Balance as of period end
2010-12-31$1.04Bn/a2011-02-04, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Biogen Inc. (BIIB)2025-12-31$6.29B-0.1%
Gilead Sciences, Inc. (GILD)2025-12-31$24.94B-6.6%
Amgen Inc (AMGN)2025-12-31$54.60B-9.1%
Qiagen N.V. (QGEN)2025-12-31$1.65B+18.9%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.14B+42.3%
Repligen Corp (RGEN)2025-12-31$542.21M+3.2%
ADMA Biologics, Inc. (ADMA)2025-12-31$72.14M-0.3%
Tarsus Pharmaceuticals, Inc. (TARS)2025-12-31$72.44M+0.8%
Adaptimmune Therapeutics PLC (ADAPY)2024-12-31$54.28Mn/a

Compare BIIB, GILD, AMGN, QGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗